Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex

Emerg Microbes Infect. 2023 Dec;12(1):2148563. doi: 10.1080/22221751.2022.2148563.

Abstract

Subacute sclerosing panencephalitis (SSPE) is a late-onset and fatal viral disease caused by persistent infection of the central nervous system by measles virus (MeV). We present the case of a 10-year-old child from South Asia affected by SSPE, stabilized with a combination of intrathecal interferon-α2b (INF-α2b) injections and oral inosiplex and how we continued the treatment when inosiplex was commercially stopped worldwide.

Keywords: Inosiplex; inosine pranobex; magistral preparation; speciality commercially stopped; subacute sclerosing panencephalitis (SSPE).

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Asia, Southern
  • Child
  • Humans
  • Inosine Pranobex* / therapeutic use
  • Interferon-alpha / therapeutic use
  • Subacute Sclerosing Panencephalitis* / drug therapy

Substances

  • Inosine Pranobex
  • Interferon-alpha

Grants and funding

This research was partially funded by LabEx ARCANE, ANR-11-LABX-0003-01.